Franklin Berger Overview

  • Investor Type
  • Angel
  • Investments
  • 2
  • Portfolio
  • 1
  • Exits
  • 1
Exits

Franklin Berger General Information

Description

Mr. Franklin Berger served as Chairman at Proteostasis Therapeutics. He joined Proteostasis Therapeutics Board of Directors in February 2016. He also serves as Board Member at Rain Therapeutics. Mr. Berger is a consultant to biotechnology industry participants, including major pharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies, providing business development, strategic advisory, financing, partnering, and royalty acquisition advice. Mr. Berger is also a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. Mr. Berger worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from January 2007 through May 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of BELLUS Health, Inc. (OTCPK: BLUSF), ESSA Pharma, Inc. (NASDAQ: EPIX), Immune Design Corp. (NASDAQ: IMDZ) and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), each of which is a public biotechnology company. Mr. Berger formerly served on the boards of Seattle Genetics, Inc. (NASDAQ: SGEN), Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) and Emisphere Technologies, Inc., BioTime, Inc. and VaxGen, Inc., each of which was public pharmaceutical companies during Mr. Berger's service as a director. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School. He is also a Chartered Financial Analyst.

Contact Information

Primary Investor Type
Angel (individual)
Primary Office
  • 545 Fifth Avenue
  • Suite 1400
  • New York, NY 10017
  • United States
+1 (212) 000-0000

Franklin Berger Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Amphivena Therapeutics 24-Sep-2019 Later Stage VC 0000 Biotechnology Generating Revenue 00000000 000000
0000000 0000000000 08-Feb-2017 00000 00000 00.000 Biotechnology Generating Revenue
To view Franklin Berger’s complete investments history, request access »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Franklin Berger Exits (1)

Company Name Exit Date Exit Type Exit Size
0000000 0000000000 14-May-2019 000 0000
To view Franklin Berger’s complete exits history, request access »

Franklin Berger Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Franklin Berger Team (1)

Name Title Deals Funds Boards Office
Franklin Berger Angel Investor 0 0 New York, NY
To view Franklin Berger’s complete team members history, request access »

Franklin Berger Co-Investors (18)

Name With Exits Lead Partner Series Industry
Industrial Investors Group 1 0 Series chart Industry bar
MPM Capital 0 0 Series chart Industry bar
ND Capital 0 0 Series chart Industry bar
Qiming Venture Partners 0 0 Series chart Industry bar
Tekla Capital Management 0 0 Series chart Industry bar
You’re viewing 5 of 18 co-investors. Get the full list »